Agio Capital is happy and proud to have successfully supported another deal: the acquisition of Apitope by Worg Pharmaceuticals.
It’s all hard work, but it pays off!!
Worg Pharmaceuticals (Hangzhou, China), a clinical stage biopharmaceutical company which develops new treatments for allergy, has entered into an asset purchase agreement under which Worg will acquire Apitope’s proprietary platform and therapeutic pipeline.
Apitope (Diepenbeek, Belgium) is a clinical stage biotech company that develops potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases.
The deal is a win-win. Worg will drive the development of Apitope’s promising pipeline of first-in-class immunotherapies to give patients novel, effective and safe treatments. The combination of Apitope’s innovative programs and Worg’s drug development expertise will maximise the potential of these projects and address significant unmet medical needs.
More info about the transaction, can be found here.
Stay tuned for more news. More deals surely to follow soon!
